FACS analysis showed the presence of myeloid cells (CD33+) and erythroid cells (GPA+) at day 14, confirming the differentiation capability of the CD34+ hematopoietic progenitors derived from the CML-iPSCs (Fig 6E). The gene discussed is GYPA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.